Cite
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
MLA
Goss, Glenwood, et al. “Osimertinib for Pretreated EGFR Thr790Met-Positive Advanced Non-Small-Cell Lung Cancer (AURA2): A Multicentre, Open-Label, Single-Arm, Phase 2 Study.” The Lancet. Oncology, vol. 17, no. 12, Dec. 2016, pp. 1643–52. EBSCOhost, https://doi.org/10.1016/S1470-2045(16)30508-3.
APA
Goss, G., Tsai, C.-M., Shepherd, F. A., Bazhenova, L., Lee, J. S., Chang, G.-C., Crino, L., Satouchi, M., Chu, Q., Hida, T., Han, J.-Y., Juan, O., Dunphy, F., Nishio, M., Kang, J.-H., Majem, M., Mann, H., Cantarini, M., Ghiorghiu, S., & Mitsudomi, T. (2016). Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. The Lancet. Oncology, 17(12), 1643–1652. https://doi.org/10.1016/S1470-2045(16)30508-3
Chicago
Goss, Glenwood, Chun-Ming Tsai, Frances A Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee-Chen Chang, Lucio Crino, et al. 2016. “Osimertinib for Pretreated EGFR Thr790Met-Positive Advanced Non-Small-Cell Lung Cancer (AURA2): A Multicentre, Open-Label, Single-Arm, Phase 2 Study.” The Lancet. Oncology 17 (12): 1643–52. doi:10.1016/S1470-2045(16)30508-3.